Key facts
- This page summarizes Peter Libby's Form 4 filing for XBiotech Inc. (XBIT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Jul 2021, 11:48.
Peter Libby - 09 Jul 2021 Form 4 Insider Report for XBiotech Inc. (XBIT)
- Reporting relationship
- Director
- Issuer ticker
- XBIT
- Reported as of
- 09 Jul 2021
- Net transaction value
- +$194,000
- SEC form
- 4
- Accepted by SEC
- 12 Jul 2021, 11:48:22 UTC
- Prior SEC filing
- 24 Jun 2021
- Next SEC filing
- 27 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Queena Han under Power of Attorney for Peter Libby
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter Libby filed Form 4 for XBiotech Inc. (XBIT) on 12 Jul 2021.
Change
- Previous filing in this sequence was filed on 24 Jun 2021.
- Current net transaction value: +$194,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XBIT
transaction
Common Shares
Options Exercise
- Transaction value
- $194,000
- Shares
- +25,000
- Change %
- Price
- $7.76
- Shares after
- 25,000
- Date
- 09 Jul 2021
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XBIT
transaction
Derivative
Stock options
Options Exercise
- Transaction value
- $0
- Shares
- -25,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 09 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stocks
- Underlying amount
- 25,000
- Exercise price
- $7.76
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
The Reporting Person exercised and purchased the 25,000 shares of common stock on July 09, 2021